ClearMed
All Gastroenterology BriefingsThe Lancet Gastroenterology & Hepatology
GastroenterologyReal-World Cohort3 min read

Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study

Unlocking the Genetic Link Between Liver Failure and Kidney Damage.

Published in The Lancet Gastroenterology & HepatologyGenetic / Mendelian study
5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Source

Gold-Standard Human Evidence

5/5

Scientists have pinpointed a specific gene, SUSD1, that significantly increases the risk of kidney problems in people with severe liver disease. This gene's impact appears to change depending on how advanced the liver disease is.

What Changes?

Gastroenterology · Real-World Cohort

Current Standard

Conventional gastroenterology practice relies on standard-of-care monitoring and existing regimens prior to this genetic / mendelian study.

New Finding

This discovery offers a crucial new understanding of how liver and kidney health are connected.

3 Key Takeaways

Plain English Summary
  1. 01Core Finding

    Until now, the genetic reasons behind this risk were largely a mystery.

  2. 02Study Evidence

    Tested in a genetic / mendelian study at the real-world cohort stage.

  3. 03Practical Meaning

    It could pave the way for earlier detection and more targeted treatments for kidney complications in liver disease patients.

What This Means for You

This discovery offers a crucial new understanding of how liver and kidney health are connected. It could pave the way for earlier detection and more targeted treatments for kidney complications in liver disease patients.

The Discovery

For people with severe liver disease, kidney failure is a dangerous complication. Until now, the genetic reasons behind this risk were largely a mystery. A groundbreaking study, analyzing genetic data from thousands of patients, has identified a key genetic marker: the SUSD1 gene. This gene's influence on kidney risk was particularly strong in those with advanced liver disease, but not in individuals with milder forms or the general population. The research also suggests that this gene might be involved in a specific immune pathway, potentially linking liver dysfunction to kidney injury.

How It Works, Simply

This gastroenterology research focuses on genetics. Researchers evaluated it using a genetic / Mendelian study at the real-world cohort stage of medical research.

3 Key Takeaways

Clinical Takeaways
  1. 01Core Finding

    Until now, the genetic reasons behind this risk were largely a mystery.

  2. 02Study Evidence

    Tested in a genetic / mendelian study at the real-world cohort stage.

  3. 03Practical Meaning

    It could pave the way for earlier detection and more targeted treatments for kidney complications in liver disease patients.

01

Biological Mechanism & Study Design

Study Design & Cohort

Genetic / Mendelian study

Genetic / Mendelian study · Real-World Cohort

Biological Pathway & Modality

Genetics

Intervention: Genetic variants and the risk of renal impairment in decompensated : a

02

Experimental Findings & Endpoints

For people with severe liver disease, kidney failure is a dangerous complication.

Until now, the genetic reasons behind this risk were largely a mystery. A groundbreaking study, analyzing genetic data from thousands of patients, has identified a key genetic marker: the SUSD1 gene.

This gene's influence on kidney risk was particularly strong in those with advanced liver disease, but not in individuals with milder forms or the general population. The research also suggests that this gene might be involved in a specific immune pathway, potentially linking liver dysfunction to kidney injury.

03

Clinical Translation & Practice Context

This discovery offers a crucial new understanding of how liver and kidney health are connected.

It could pave the way for earlier detection and more targeted treatments for kidney complications in liver disease patients.

03

The Bottom Line · Clinical Pearl

“Scientists have pinpointed a specific gene, SUSD1, that significantly increases the risk of kidney problems in people with severe liver disease. This gene's impact appears to change depending on how advanced the liver disease is.”

Published in The Lancet Gastroenterology & Hepatology · Current Stage: Real-World Cohort

Gastroenterology · Real-World Cohort
Study Type
Genetic / Mendelian study

Genetic / Mendelian study

Evidence Score
5/5 · Gold-Standard Human Evidence
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

Who It Applies To
Individuals with milder forms or the general population
Intervention & Mechanism
Genetic variants and the risk of renal impairment in decompensated cirrhosis: a

Genetics

Key Limitation
Genetic / Mendelian randomization findings highlight causal biological risk, but ancestry coverage and pleiotropy can limit generalizability.

Translational Stage

LEVEL 2 · Real-World Cohort

Classified as Genetic / Mendelian study along the clinical evidence continuum

  1. Lab & Discovery
  2. Early Trials
  3. Human Evidence
  4. 4Real-World CohortActive

Original Publication & AMA Citation

Genetic variants and the risk of renal impairment in decompensated cirrhosis: a multi-ancestry genome-wide association study. The Lancet Gastroenterology & Hepatology. Published 2026;Nov 15. Accessed November 15, 2026. https://pubmed.ncbi.nlm.nih.gov/42759531/

The Lancet Gastroenterology & Hepatology

https://pubmed.ncbi.nlm.nih.gov/42759531/

Read Original Paper

Continue Reading

Related in Gastroenterology

View all Gastroenterology briefings →
GASTROENTEROLOGY · REAL-WORLD COHORT

Prevalence of liver fibrosis and steatotic liver disease in community-dwelling adults in China (the CHESS-LiverHealth project): cross-sectional baseline data from a prospective cohort study

Silent Liver Damage: A Hidden Epidemic in China's Adult Population. Liver scarring and fatty liver disease are widespread among Chinese adults, largely fueled by metabolic issues and alcohol.

4/5 Strong Trial
Evidence Meter · 4/5

Strong Clinical Evidence

Tested directly in patients through a prospective clinical trial or large multicenter human cohort.

1 min readThe Lancet Gastroenterology & Hepatology
Gastroenterology editorial photograph for Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial
GASTROENTEROLOGY · PHASE III

Aspirin after curative-intent treatment of colorectal cancer liver metastases (ASAC): a multicentre, phase 3, randomised, double-blind, placebo-controlled trial

Aspirin After Colon Cancer: A Surprising Setback for a Common Drug. Taking aspirin after surgery for colon cancer that spread to the liver did not prevent the cancer from returning and was linked to worse survival and more serious side effects.

5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readThe Lancet Gastroenterology & Hepatology
GASTROENTEROLOGY · CLINICAL PRACTICE

AGA/AASLD Clinical Practice Guideline on Management of Primary Biliary Cholangitis

The guideline emphasizes early diagnosis, optimization of first-line therapy, risk-based treatment escalation, symptom management, and prevention of post-transplantation disease recurrence to improve patient outcomes and quality of life. Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease associated with progressive fibrosis (tissue scarring), cirrhosis, liver transplantation, and premature risk of death.

5/5 Gold Standard
Evidence Meter · 5/5

Gold-Standard Human Evidence

Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.

1 min readGastroenterology